Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Nervous Markets Rebound As Ukraine Tensions Fade ↗

February 23, 2022

U.S. President Joe Biden said Russia had started to invade Ukraine and announced steps targeting Russia’s sale of sovereign debt abroad, its elites and a pair of banks.

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 23, 2022

Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023 ↗

February 23, 2022

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial...

Via Benzinga

23 Stocks Moving in Wednesday's Pre-Market Session ↗

February 23, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 22, 2022

Gainers Revelation Biosciences (NASDAQ:REVB

Via Benzinga

Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

February 22, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022

February 16, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 10, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update

February 03, 2022

From Marinus Pharmaceuticals

Via Business Wire

Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)

January 19, 2022

Via AB Newswire

Topics Bonds Stocks

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 14, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference

January 05, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 27, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

December 03, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting

November 22, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

November 15, 2021

From Marinus Pharmaceuticals

Via Business Wire

Recap: Marinus Pharmaceuticals Q3 Earnings ↗

November 09, 2021

Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the...

Via Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

November 09, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 08, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

October 26, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder

October 25, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 08, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

October 05, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

September 28, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

September 20, 2021

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2021

From Marinus Pharmaceuticals

Via Business Wire

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder

August 26, 2021

From Marinus Pharmaceuticals, Inc.

Via Business Wire

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

August 25, 2021

From Marinus Pharmaceuticals

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 18, 2021

Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading volume for PharmaCyte Biotech's stock is 144.3...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.